Progentos Therapeutics secures $65M Series A funding led by Forbion to advance MS program and expand pipeline for other diseases.
Progentos Therapeutics, a biotech focused on regenerating myelin for Multiple Sclerosis (MS) and other degenerative diseases, closed a $65 million Series A financing round led by Forbion. The funding will advance its MS program through human proof of concept studies and expand the pipeline for additional diseases. Progentos, founded by CEO Dr. Chris Loose, is developing first-in-class small molecules to induce remyelination of axons affected by MS.
May 20, 2024
3 Articles